Anacor Pharmaceuticals Company Profile (NASDAQ:ANAC)

About Anacor Pharmaceuticals

Anacor Pharmaceuticals logoAnacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ANAC
  • CUSIP: 03242010
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $93.23
  • 200 Day Moving Average: $81.52
  • 52-Week Range: $52.00 - $156.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -162.62
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Anacor Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Anacor Pharmaceuticals (NASDAQ:ANAC) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $101.17 (1.98% upside)

Analysts' Ratings History for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateFirmActionRatingPrice TargetDetails
5/18/2016MizuhoDowngradeBuy -> Neutral$98.00 -> $99.25View Rating Details
5/16/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
5/16/2016WedbushDowngradeOutperform -> Neutral$148.00 -> $99.25View Rating Details
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/9/2015JMP SecuritiesInitiated CoverageOutperform$173.00View Rating Details
7/21/2015Bank of America CorpUpgradeNeutral -> BuyView Rating Details
7/21/2015Goldman Sachs Group, Inc. (The)UpgradeNeutral -> Buy$195.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.35)($0.36)$19.53 million$17.54 millionViewListenView Earnings Details
2/29/2016Q415($0.30)($0.43)$27.93 million$21.20 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.37)$25.60 million$24.60 millionViewListenView Earnings Details
8/6/2015Q215($0.32)($0.30)$18.55 million$21.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.49)($0.30)$9.20 million$15.26 millionViewN/AView Earnings Details
3/12/2015Q414($0.61)($0.24)$4.74 million$9.60 millionViewN/AView Earnings Details
11/6/2014Q314($0.66)($0.74)$3.67 million$3.96 millionViewN/AView Earnings Details
8/7/2014Q214($0.63)($0.58)$3.03 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.39)($0.51)$2.82 million$4.15 millionViewN/AView Earnings Details
3/13/2014Q413($0.39)$3.01$2.85 million$8.50 millionViewN/AView Earnings Details
11/7/2013Q313($0.39)($0.41)$2.57 million$3.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.39)($0.36)$2.60 million$3.40 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.42)$2.57 million$1.71 billionViewN/AView Earnings Details
3/14/2013Q4 2012($0.45)($0.36)$3.25 million$3.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.45)($0.46)$3.18 million$2.47 millionViewN/AView Earnings Details
8/9/2012($0.45)($0.47)ViewN/AView Earnings Details
5/10/2012($0.44)($0.48)ViewN/AView Earnings Details
3/13/2012($0.35)($0.52)ViewN/AView Earnings Details
11/10/2011($0.41)($0.16)ViewN/AView Earnings Details
8/11/2011($0.45)($0.54)ViewN/AView Earnings Details
5/5/2011($0.31)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Anacor Pharmaceuticals (NASDAQ:ANAC)
Current Year EPS Consensus Estimate: $-1.58 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.45)($0.30)($0.38)
Q2 20162($0.41)($0.36)($0.39)
Q3 20162($0.44)($0.33)($0.39)
Q4 20162($0.74)($0.53)($0.64)
Q1 20171($0.53)($0.53)($0.53)
Q2 20171$0.52$0.52$0.52
Q3 20171$1.32$1.32$1.32
Q4 20171$1.67$1.67$1.67
(Data provided by Zacks Investment Research)


Dividend History for Anacor Pharmaceuticals (NASDAQ:ANAC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Anacor Pharmaceuticals (NASDAQ:ANAC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Graeme BellCFOSell751$99.28$74,559.28View SEC Filing  
5/23/2016Keith R LeonardDirectorSell9,000$99.70$897,300.00View SEC Filing  
5/16/2016Anders D HoveDirectorSell353,881$99.59$35,243,008.79View SEC Filing  
4/29/2016Ryan T SullivanEVPSell3,125$66.33$207,281.25View SEC Filing  
4/8/2016Anders D HoveDirectorSell229,301$71.10$16,303,301.10View SEC Filing  
3/22/2016Paul L BernsCEOSell37,500$60.31$2,261,625.00View SEC Filing  
1/19/2016Vincent P. IppolitoEVPSell20,000$95.41$1,908,200.00View SEC Filing  
1/15/2016Lee ZaneSVPSell1,466$89.57$131,309.62View SEC Filing  
1/4/2016Paul L. BernsCEOSell2,533$112.35$284,582.55View SEC Filing  
1/4/2016Ryan T. SullivanVPSell733$111.78$81,934.74View SEC Filing  
1/4/2016Vincent P. IppolitoEVPSell855$112.28$95,999.40View SEC Filing  
12/11/2015Paul L. BernsCEOSell20,000$117.26$2,345,200.00View SEC Filing  
12/10/2015Ryan T. SullivanVPSell10,000$110.41$1,104,100.00View SEC Filing  
9/15/2015Lee ZaneSVPSell14,000$139.84$1,957,760.00View SEC Filing  
9/15/2015Paul L. BernsCEOSell20,000$139.83$2,796,600.00View SEC Filing  
8/13/2015Paul L BernsCEOSell20,000$138.69$2,773,800.00View SEC Filing  
6/15/2015Lee ZaneSVPSell12,000$69.05$828,600.00View SEC Filing  
5/15/2015Jacob J PlattnerVPSell8,920$63.73$568,471.60View SEC Filing  
5/14/2015Carmen R RodriguezVPSell61,942$62.73$3,885,621.66View SEC Filing  
4/29/2015Ryan T SullivanVPSell3,125$53.61$167,531.25View SEC Filing  
4/27/2015Paul L BernsCEOSell50,000$63.64$3,182,000.00View SEC Filing  
4/15/2015Jacob J PlattnerVPSell8,920$62.81$560,265.20View SEC Filing  
3/23/2015Geoffrey M ParkerCFOBuy3,000$52.43$157,290.00View SEC Filing  
3/16/2015Jacob J PlattnerVPSell8,920$55.60$495,952.00View SEC Filing  
3/16/2015Lee ZaneSVPSell12,000$56.44$677,280.00View SEC Filing  
3/4/2015Sanjay ChandaSVPSell5,000$45.00$225,000.00View SEC Filing  
3/3/2015Vincent P IppolitoEVPSell9,000$43.88$394,920.00View SEC Filing  
3/2/2015Jacob J PlattnerVPSell6,875$44.02$302,637.50View SEC Filing  
3/2/2015Kirk R MaplesSVPSell600$43.95$26,370.00View SEC Filing  
1/2/2015Jacob J PlattnerVPSell6,875$32.09$220,618.75View SEC Filing  
12/26/2014Paul L BernsCEOSell25,000$30.82$770,500.00View SEC Filing  
12/12/2014Lucy ShapiroDirectorSell289,685$35.11$10,170,840.35View SEC Filing  
12/11/2014Lee ZaneSVPSell4,900$36.09$176,841.00View SEC Filing  
12/9/2014Kirk R MaplesSVPSell60,000$36.52$2,191,200.00View SEC Filing  
12/1/2014Jacob J PlattnerVPSell6,875$33.34$229,212.50View SEC Filing  
12/1/2014Kirk R MaplesSVPSell600$33.38$20,028.00View SEC Filing  
11/26/2014Sanjay ChandaSVPSell5,000$35.00$175,000.00View SEC Filing  
11/3/2014Jacob J PlattnerVPSell6,875$29.32$201,575.00View SEC Filing  
10/1/2014Jacob J PlattnerVPSell6,875$24.47$168,231.25View SEC Filing  
9/26/2014Anders D HoveDirectorSell20,000$25.00$500,000.00View SEC Filing  
9/19/2014Anders D HoveDirectorSell740,000$24.87$18,403,800.00View SEC Filing  
9/16/2014Anders D HoveDirectorSell90,000$24.99$2,249,100.00View SEC Filing  
9/10/2014Sanjay ChandaSVPSell10,000$24.25$242,500.00View SEC Filing  
9/8/2014Geoffrey M ParkerCFOBuy6,590$21.82$143,793.80View SEC Filing  
8/27/2014Mark LeschlyDirectorSell13,067$22.50$294,007.50View SEC Filing  
5/20/2014Kirk MaplesSVPSell1,500$14.15$21,225.00View SEC Filing  
4/21/2014Kirk MaplesSVPSell1,500$15.60$23,400.00View SEC Filing  
3/24/2014Geoffrey ParkerCFOBuy5,000$20.11$100,550.00View SEC Filing  
3/21/2014Lucy ShapiroDirectorSell80,000$21.14$1,691,200.00View SEC Filing  
3/20/2014Kirk MaplesSVPSell3,000$22.39$67,170.00View SEC Filing  
3/18/2014Geoffrey ParkerCFOBuy2,410$22.60$54,466.00View SEC Filing  
3/5/2014David PerryCEOSell65,000$20.22$1,314,300.00View SEC Filing  
2/20/2014Kirk MaplesSVPSell3,000$19.33$57,990.00View SEC Filing  
2/5/2014David PerryCEOSell15,000$17.00$255,000.00View SEC Filing  
1/21/2014Kirk MaplesSVPSell3,000$20.27$60,810.00View SEC Filing  
1/9/2014David PerryCEOSell65,000$16.32$1,060,800.00View SEC Filing  
12/9/2013David PerryCEOSell40,328$16.23$654,523.44View SEC Filing  
11/26/2013Geoffrey ParkerCFOBuy10,000$13.40$134,000.00View SEC Filing  
11/25/2013Geoffrey ParkerCFOBuy10,000$12.85$128,500.00View SEC Filing  
8/14/2013Kirk MaplesSVPSell1,052$9.71$10,214.92View SEC Filing  
8/13/2013Geoffrey ParkerCFOBuy50,000$8.34$417,000.00View SEC Filing  
6/19/2013Geoffrey M ParkerCFOBuy23,046$5.20$119,839.20View SEC Filing  
6/18/2013Geoffrey M ParkerCFOBuy20,000$5.22$104,400.00View SEC Filing  
6/14/2013Kirk R MaplesSVPSell5,600$5.39$30,184.00View SEC Filing  
11/26/2012Kirk R MaplesSVPSell3,000$5.22$15,660.00View SEC Filing  
11/1/2012Kirk R MaplesSVPSell3,000$5.81$17,430.00View SEC Filing  
10/5/2012Lucy ShapiroDirectorSell30,000$6.67$200,100.00View SEC Filing  
8/22/2012Geoffrey M ParkerCFOBuy5,000$6.19$30,950.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateHeadline logoPTAB Invalidates Two Anacor Patents In Hedge Fund Challenge - Law360 (subscription) (NASDAQ:ANAC) - February 24 at 8:46 PM logoThese Were the 10 Biggest Pharmaceutical Deals of 2016 - Fortune (NASDAQ:ANAC) - February 24 at 3:44 PM
News IconAnalysts Peer Into Their Crystal Balls For Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC): Where Is It headed? - Winfield Review (NASDAQ:ANAC) - February 23 at 8:33 PM
News IconGlobal Dermatophytic Onychomycosis Market to Spread a Predictable Worth of US$ 4,706.3 Million by 2021 – Persistence Market Research (NASDAQ:ANAC) - February 23 at 1:35 AM logoBetter Buy: Pfizer Inc. vs. Merck & Co. Inc. -- The Motley Fool - Motley Fool (NASDAQ:ANAC) - February 21 at 3:48 PM
News IconAnacor Pharmaceuticals, Inc. (NASDAQ:ANAC) Updated Broker Ratings - NewsDen (NASDAQ:ANAC) - February 21 at 3:48 PM
News IconBetter Buy: Gilead Sciences, Inc. vs. Pfizer Inc. - (NASDAQ:ANAC) - February 19 at 7:31 AM
News IconIs The Sell-Side Predicting That Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) Will Move Higher? - Winfield Review (NASDAQ:ANAC) - February 16 at 3:36 PM logo4 High-Yield Dividend Stocks You Don't Have to Babysit - Motley Fool (NASDAQ:ANAC) - February 16 at 8:27 AM
News IconAre Analysts Optimistic About Where Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) is Heading? - Winfield Review (NASDAQ:ANAC) - February 16 at 8:27 AM
News IconGlobal Atopic Dermatitis Treatment Sales Market Report Forecast 2016-2021 (NASDAQ:ANAC) - February 11 at 2:01 AM
News IconDermatophytic Onychomycosis Therapeutics Market: Global Market Intelligence (NASDAQ:ANAC) - February 11 at 2:01 AM logoDermatophytic Onychomycosis Market is Anticipated to Grow US$ 4,706.3 Million by 2021 (NASDAQ:ANAC) - February 9 at 8:36 PM
News IconDermatophytic Onychomycosis Market is Anticipated to Grow US$ 4706.3 Million by 2021 - Satellite PR News (press release) (NASDAQ:ANAC) - February 9 at 3:35 PM logoPfizer Inc. (PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program (NASDAQ:ANAC) - February 7 at 8:44 PM logoPfizer Inc. (NYSE:PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program - Market Exclusive (NASDAQ:ANAC) - February 7 at 3:41 PM
News IconGlobal Dermatophytic Onychomycosis Market to Extent an Assessed ... - Satellite PR News (press release) (NASDAQ:ANAC) - February 6 at 3:18 PM
News IconPfizer clocks net profit of US$ 775 mn in Q4 as against loss of $172 mn (NASDAQ:ANAC) - February 3 at 2:49 AM
News IconPfizer clocks net profit of US$ 775 mn in Q4 as against loss of $172 mn - (NASDAQ:ANAC) - February 2 at 3:32 PM logoAnacorAcquisition Added Crisaborole to Pfizer’s Portfolio (NASDAQ:ANAC) - February 2 at 1:54 AM
News Icon3 Pharmaceutical Stocks With Bigger Dividends Than Johnson ... - (NASDAQ:ANAC) - February 1 at 8:40 PM logo5 Things Pfizer's Management Wants You to Know - Motley Fool (NASDAQ:ANAC) - February 1 at 3:37 PM logoTop 5 Vendors in the Global Atopic Dermatitis Drugs Market from 2017 to 2021: Technavio - Business Wire (press release) (NASDAQ:ANAC) - February 1 at 3:37 PM
News IconStock Earnings in Review: Pfizer Inc. (NYSE:PFE) - Post Registrar (NASDAQ:ANAC) - February 1 at 3:37 PM logoPfizer Seeks Deals as Generic Versions Hurts Older Drugs’ Sales (NASDAQ:ANAC) - February 1 at 1:44 AM
News IconPFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS (NASDAQ:ANAC) - February 1 at 1:44 AM logoAre Pfizer's Acquisitions Holding Back Its Bottom Line? - 24/7 Wall St. (NASDAQ:ANAC) - January 31 at 3:42 PM logo3 Reasons to Buy Pfizer Stock and Never Sell -- The Motley Fool - Motley Fool (NASDAQ:ANAC) - January 31 at 2:25 AM logoAll Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter ... - (NASDAQ:ANAC) - January 31 at 2:25 AM
News Icon3 Top Pharmaceutical Stocks to Buy in February - (NASDAQ:ANAC) - January 30 at 3:54 PM logoA Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour - Benzinga (NASDAQ:ANAC) - January 30 at 3:54 PM
News Icon3 Reasons to Buy Pfizer Stock and Never Sell - (NASDAQ:ANAC) - January 29 at 3:29 PM
News IconBetter Buy: Pfizer Inc. vs. Johnson & Johnson - Fox Business (NASDAQ:ANAC) - January 27 at 9:24 PM
News IconBetter Buy: Pfizer Inc. vs. Johnson & Johnson - (NASDAQ:ANAC) - January 27 at 4:20 PM logoWhat Lies in Store for Pfizer (PFE) this Earnings Season? - Yahoo Finance (NASDAQ:ANAC) - January 25 at 3:37 PM logoDrugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees - (NASDAQ:ANAC) - January 24 at 8:28 PM
News IconEarnings in Full Force, Analysts Take Aim at Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) - Wall Street Beacon (NASDAQ:ANAC) - January 24 at 3:21 PM
News IconBetter Buy: Merck & Co. Inc. vs. Pfizer | Fox Business - Fox Business (NASDAQ:ANAC) - January 23 at 3:36 PM
News IconFDA approves Eucrisa for eczema - Satellite PR News (press release) (NASDAQ:ANAC) - January 22 at 8:31 PM
News IconBetter Buy: Merck & Co. Inc. vs. Pfizer - (NASDAQ:ANAC) - January 22 at 3:29 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) - Wall Street Beacon (NASDAQ:ANAC) - January 20 at 2:01 AM
News IconWill The Needle Move For Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ANAC) - January 17 at 3:45 PM
News Icon3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference ... - (NASDAQ:ANAC) - January 12 at 3:34 PM
News IconUSFDA approves Eucrisa for eczema (NASDAQ:ANAC) - January 11 at 1:36 AM
News Icon2 Reasons Pfizer's Stock Beat the Field in 2016 - (NASDAQ:ANAC) - January 9 at 3:44 PM
News IconBetter Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer - Fox Business (NASDAQ:ANAC) - January 8 at 3:29 PM
News IconBetter Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer - (NASDAQ:ANAC) - January 7 at 3:58 PM
News IconAnacor Pharmaceuticals Inc ANAC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ANAC) - January 6 at 1:49 AM logoPfizer Is Cheap, but Is Still a Dog Stock - TheStreet - (NASDAQ:ANAC) - January 4 at 3:39 PM logoGlobal Medicated Skin Care Products - Consumer Healthcare - PR Newswire (press release) (NASDAQ:ANAC) - January 4 at 3:39 PM


What is Anacor Pharmaceuticals' stock symbol?

Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."

Where is Anacor Pharmaceuticals' stock going? Where will Anacor Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 1 year price objectives for Anacor Pharmaceuticals' stock. Their predictions range from $99.25 to $105.00. On average, they expect Anacor Pharmaceuticals' stock price to reach $101.17 in the next twelve months.

When will Anacor Pharmaceuticals announce their earnings?

Anacor Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 4th 2016.

What are analysts saying about Anacor Pharmaceuticals stock?

Here are some recent quotes from research analysts about Anacor Pharmaceuticals stock:

  • According to Zacks Investment Research, "Anacor Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovery, development and commercialization of novel small-molecule therapeutics derived from its boron chemistry platform. Its three lead product candidates include two topically administered dermatologic compounds-AN2690, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria-GSK2251052. Additionally, the Company also develops topical antifungal product for the treatment of onychomycosis and skin fungal infections, topical anti-inflammatory product for the treatment of psoriasis and atopic dermatitis. Anacor Pharmaceuticals, Inc. is headquartered in Palo Alto, California. " (5/12/2016)

  • Jefferies Group LLC analysts commented, "We provide the following data points related to Anacor from our meetings at this year’s AAD conference. Please see our full wrap-up note for more details. Palpable "Buzz" for Next Generation AD Therapies Including Anacor’s Crisaborole and Sanofi/Regeneron’s Dupulimab: There was undoubtedly quite a bit of "buzz" for two novel atopic dermatitis (AD) drugs at this year’s event – including Anacor’s topical PDE4 inhibitor Crisaborole for mild/moderate AD and Sanofi/Regeneron’s IL4/IL13 inhibitor Dupilumab for moderate/severe AD. Doctors we spoke with were universally very enthusiastic about each drug, with the focus on Crisaborole mostly related to its topical administration route and pristine safety profile while the conversation surrounding Dupilumab also related to its clean safety profile and outstanding efficacy in the most difficult to treat patients." (3/10/2016)

How do I buy Anacor Pharmaceuticals stock?

Shares of Anacor Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Anacor Pharmaceuticals stock cost?

One share of Anacor Pharmaceuticals stock can currently be purchased for approximately $99.20.

Anacor Pharmaceuticals (NASDAQ:ANAC) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)

Earnings History Chart

Earnings by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)

Dividend History Chart

Dividend Payments by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)

Last Updated on 2/24/2017 by Staff